NasdaqGS:INSMBiotechs
What Insmed (INSM)'s 12‑Month TPIP Pulmonary Hypertension Data Means For Shareholders
On July 16, 2026, Insmed announced positive 12‑month data from its ongoing open-label extension study of once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, showing sustained improvements in six-minute walk distance, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 score, with no new safety signals identified.
A particularly striking finding was that about 65% of patients achieved Refined Low Risk status, a category associated with a very low...